 Current News and Information
News
January 14, 2009 - Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers. Based on its recent analysis of the biopharmaceuticals market, Frost & Sullivan recognizes Neotropix, Inc. with the 2009 U.S. Frost & Sullivan Award for Product Innovation of the Year. This award acknowledges the company's introduction of the innovative virotherapy NTX-010 (Seneca Valley Virus), More...
October 8, 2008 - Scripps research team solves structure of 'beneficial' virus
The 3-D structure of the virus, known as Seneca Valley Virus-001, reveals that it is unlike any other known member of the Picornaviridae viral family, and confirms its recent designation as a separate genus "Senecavirus." The new study reveals that the virus's outer protein shell looks like a craggy golf ball¬—one with uneven divets and raised spikes—and the RNA strand beneath it is arranged in a round mesh rather like a whiffleball. More...
October 8, 2008 --Neotropix® Announces Expansion of On-going Clinical Trial for Adult Neuroendocrine Cancers. Neotropix®, Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus. Neotropix® also announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) of NTX-010 for the treatment of neuroendocrine tumors. More...
September 23, 2008 -- Neotropix Appoints Anthony Williams, M.D., as its Chief Medical Officer. Neotropix™, Inc., a clinical-stage development company focused in neuroendocrine cancer treatments, today announced the appointment of Anthony Williams, M.D., as its Chief Medical Officer (CMO). Dr. Williams has more than 25 years of drug development experience, working for major pharmaceutical and biotechnology companies including GlaxoSmithKline, Merrell Dow and Dyax Corporation. More...
Presentations
Yu L, Baxter P, Zhao X, Wadhwa L, Zhang Y, Yang J, Tan X, Adesina A, Hurwitz M, Su JMF, Idamakanti N, Reddy PS, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. Oncolytic virus SVV-001 can selectively kill medulloblastoma stem cells and eradicate preformed solid tumors in primary tumor-based orthotopic xenograft mouse models Presented in 2009 at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics in Banff, Alberta, Canada.
Police SR, Idamakanti N, Finger J, Brandenburg B, Woolery N, Burroughs KD, Poirier J, Rudin CM, Hallenbeck PL. Mechanism of Tumor-Selective Tropism of Seneca Valley Virus (SVV-001), A Newly Discovered Systemically Deliverable Oncolytic Picornavirus for Treatment of Human Neuroendocrine Cancers. Presented in 2009 at the 100th Annual Meeting of the American Association for Cancer Research in Denver, Colorado.Click here to view presentation.
Baxter P, Yu L, Wadhwa L, Adesina A, Su JMF, Hurwitz MY, Zhang XM, Zhang Y, Idamakanti N, Reddy PS, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. Oncolytic virus SVV-001 selectively kills cancer stem cells and eradicates medulloblastomas in primary tumor-based intra-cerebellar xenograft mouse models. Presented in 2009 at the 100th Annual Meeting of the American Association for Cancer Research in Denver, Colorado.
Rudin CM, Williams AH, Senzer N, Stephenson J, Burroughs KD, Reddy PS, Hallenbeck PL. Phase I Trial of Seneca Valley Virus (NTX-010), a Newly Discovered Systemically Deliverable Oncolytic Picornavirus, in Patients with Solid Tumors with Neuroendocrine Features. Presented in 2009 at the Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida. Click here to view presentation.
Rudin CM, Neefe JR, Garbo L, Stephenson J, Loesch D, Von Hoff D, Smith D, Richards D, Conkling P, Alemany C, Coleman B, Burroughs K, Reddy PS, Hallenbeck PL. Phase I Trial of Seneca Valley Virus (NTX-010), a Newly Discovered Systemically Deliverable Oncolytic Picornavirus, in Patients with Solid Tumors with Neuroendocrine Features. Presented at NANETS - 2008 Neuro Endocrine Tumor Symposium held in Bermuda. Click here to view presentation.
Burroughs K, Reddy PS, Rudin CM, Neefe, JR, Garbo L, Stephenson J, Loesch D, Von Hoff D, Smith D, Richards D, Conkling P, Alemany C, Coleman B, Hallenbeck PL. Pharmacokinetics of intravenously administered Seneca valley virus (NTX-010) in a phase I trial of patients with solid tumors of neuroendocrine differentiation. NANETS – Presented at 2008 Neuro Endocrine Tumor Symposium held in Bermuda. Click here to view presentation.
Hurwitz MY, Wadhwa L, Chévez-Barrios P, Hurwitz RH. Treatment of Invasive Retinoblastoma by the Oncolytic Seneca Valley Virus. Presented at 10th 2007 American Society of Gene Therapy (ASGT) annual meeting held in Seattle, WA.
Burroughs KD, Sherk C, Johnston G, Hallenbeck PL, Neefe JR, Rudin CM. Pharmacokinetics of intravenously administered SVV-001 (NTX-010) in a Phase I trial of patients with solid tumors of neuroendocrine differentiation. Presented at the 4th International Conference on Oncolytic Viruses (2007) as Cancer Therapeutics held in Scottsdale, Arizona.
Hales LM, Jones BH, Idamakanti N, Li S, Vasko AJ, Skele KL, Sherk C, Harris J, Khare PD, Burroughs KD, Reddy PS, Hallenbeck PL. Predictive biomarkers for the prescreening of patients in clinical trials of Seneca valley virus (SVV-001), a novel oncolytic picornavirus for the systemic treatment of patients with solid tumors with neuroendocrine features. Presented at the 4th International Conference on Oncolytic Viruses (2007) as Cancer Therapeutics held in Scottsdale, Arizona.
Hallenbeck PL. Burroughs KD, Hales LM, Neefe JR, Reddy PS, Rudin CM. A phase I trial of Seneca Valley virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients having solid tumors with neuroendocrine features. Presented at the 4th International Conference on Oncolytic Viruses (2007) as Cancer Therapeutics held in Scottsdale, Arizona.
Reddy PS, Jones BH, Idamakanti N, Li S, Vasko AJ, Skele KL, Khare P, Burroughs KD, Hales LM, Hallenbeck PL. Mechanism of tumor selective replication of Seneca Valley virus (SVV-001), a novel oncolytic picornavirus for systemic treatment of patients with solid tumors with neuroendocrine features. Presented at 2007 annual meeting of American Association for Cancer Research (AACR) held in Los Angles, California.
Hallenbeck PL. Seneca Valley Virus (SVV-001), a newly discovered systemically deliverable oncolytic picornavirus for the treatment of patients with solid tumors with neuroendocrine features. Presented at 2007 annual meeting of American Association for Cancer Research (AACR) held in Los Angles, California.
Khare PD, Reddy PS, Burroughs KD, Johnston G, Idamakanti N, Jones BH, Li S, Vasko AJ, Skele KL, Sherk C, Harris J, Hales LM, Neefe JR, Hallenbeck PL. Nature of Seneca Valley Virus (SVV-001/ NTX-010) RNA in blood after systemic delivery to patients with solid tumors expressing neuroendocrine features. Presented at 2007 annual meeting of American Society of Gene Therapy (ASGT) held in Seattle, Washington.
Burroughs KD, Skele KL, Sherk CS, Jones BH, Vasko AJ, Li S, Hales LM, Reddy PS, Hallenbeck PL. Characterization of Seneca Valley Virus (SVV-001), a novel oncolytic picornavirus for systemic treatment of patients with solid tumors with neuroendocrine features. Presented at 2006 annual meeting of American Society of Gene Therapy (ASGT) held in Baltimore, Maryland.
Hales LM, Jones BH, Vasko AJ, Knowles NJ, Reddy PS, Hallenbeck PL. Epidemiology of Seneca Valley Virus (SVV-001), a novel oncolytic picornavirus for the systemic treatment of patients with solid cancers with neuroendocrine features. Presented at 2006 annual meeting of American Society of Gene Therapy (ASGT) held in Baltimore, Maryland.
Reddy PS, Idamakanti N, Jones BH, Vasko AJ, Hales LM, Kevin Burroughs KD, Hallenbeck PL. Biology and tumor selective replication of Seneca Valley virus-001, a novel oncolytic picornavirus. Presented at 2006 annual meeting of American Society for Virology (ASV) held in Madison, Wisconsin.
Knowles NJ, Hales LM, Jones BH, Landgraf JG, House JA, Skele KL, Burroughs KD, Hallenbeck PL. Epidemiology of Seneca Valley virus: Identification and characterization of isolates from pigs in the United States. Presented at EUROPIC 2005: European Study Group on the Molecular Biology of Picornaviruses XIIIth Meeting held in Lunteren, Netherlands; May 2005.
Publications
Venkataraman S, Reddy PS, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Structure of Seneca Valley Virus-001: An Oncolytic Picornavirus Representing a New Genus. Structure. 2008. 16:1555-1561.
Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele LS, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99:1623-1633.
Wadhwa L, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res. 2007;67:10653-10656.
Venkataraman S, Reddy PS, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Crystallization and preliminary X-ray diffraction studies of Seneca Valley Virus-001, a new member of the Picornaviridae Family. Acta Crystallographica;Section F: Structural Biology and Crystallization Communications. 2008; 64:293-296.
Hales LM, Knowles NJ, Reddy PS, Xu L, Hay C, Hallenbeck PL. Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. J Gen Virol. 2008;89:1265-1275.
Archives
June
23, 2006.....CEO
Paul Hallenbeck Named Ernst & Young Entrepreneur of
the Year (link)
May 17, 2006.........Neotropix
Receives
FDA Approval to Begin Clinical Trials With First Investigational
Cancer Drug (PDF)
November
1, 2005.........Dr.
Moira Gunn speaks with
Dr. Paul Hallenbeck on October 25, 2005 (link)
September 21, 2005.........Neotropix
Announces Progress in Research Program, Other Corporate Developments… Company
to Host Open House (PDF)
January 28, 2005.........Venture
Funds Favoring Firms in Life Sciences (PDF)
January 14, 2005.........Newcomer
Neotropix™ Explores Viral Therapies for Cancer (PDF)
January 9, 2005.........Turning
Viruses in Virotherapy (PDF)
2004.........Neotropix™ Nets
$10M in Private Stock Sale (PDF)
December 16, 2004.........Neotropix™ Funds
Early Operations With $10M (PDF)
December 14, 2004.........Neotropix™ Closes
$10M Series A For Development Of Virotherapy Program (PDF)
December 13, 2004.........Neotropix™ Attracts
$10 Million Series A Round For Development of Novel Virotherapies
to Treat Cancer (PDF) March 16, 2004.........Crucell
and Neotropix™ Enter PER.C6™ Licensing Agreement In the Field
of Viral Therapy (PDF) |
